Construction of a Human Aorta Smooth Muscle Cell Organ-On-A-Chip Model for Recapitulating Biomechanical Strain in the Aortic Wall
July 6th, 2022
3.2K views
Here, we developed a human aorta smooth muscle cell organ-on-a-chip model to replicate the in vivo biomechanical strain of smooth muscle cells in the human aortic wall.
Overview
This study presents a human aorta smooth muscle cell organ-on-a-chip model designed to replicate the biomechanical strain experienced by smooth muscle cells in the human aortic wall. This innovative platform allows for the simulation of mechanical stimuli and can be utilized for drug screening and personalized medicine in the context of aortic diseases.
Key Study Components
Area of Science
- Biomedical Engineering
- Cardiovascular Research
- Cellular Biology
Background
- Understanding the mechanical environment of smooth muscle cells is crucial for studying aortic diseases.
- Current models do not adequately replicate the in vivo conditions experienced by these cells.
- Patient-derived cells can enhance the relevance of in vitro studies.
- Organ-on-a-chip technology offers a novel approach to mimic physiological conditions.
Purpose of Study
- To develop a model that accurately simulates the biomechanical stimuli of smooth muscle cells in the aorta.
- To provide a platform for drug screening relevant to aortic diseases.
- To facilitate personalized medicine approaches using patient-derived cells.
Methods Used
- Harvesting smooth muscle cells from the media layer of the human aorta.
- Utilizing organ-on-a-chip technology to recreate mechanical parameters.
- Combining patient-derived cells with the organ-on-a-chip model.
- Demonstrating the procedure through a presentation by a laboratory researcher.
Main Results
- The model successfully mimics the mechanical environment of smooth muscle cells.
- It allows for precise control of mechanical parameters.
- Demonstrated potential for drug screening applications.
- Provides insights into the pathogenesis of aortic diseases.
Conclusions
- This organ-on-a-chip model represents a significant advancement in studying aortic diseases.
- It opens new avenues for personalized medicine and drug development.
- Future studies can leverage this model to further understand aortic disease mechanisms.
Frequently Asked Questions
What is the significance of the organ-on-a-chip model?
The model replicates the biomechanical environment of smooth muscle cells, enhancing the study of aortic diseases.
How can this model be used in drug screening?
It allows for testing drug responses in a controlled environment that mimics human physiology.
What types of cells are used in this study?
Patient-derived smooth muscle cells from the human aorta are utilized.
Who demonstrated the procedure?
Mieradilijiang Abudubat, a poster doctor from the laboratory, demonstrated the procedure.
What are the potential applications of this research?
Applications include personalized medicine and improved drug screening for aortic diseases.
What are the main results of this study?
The model successfully mimics the mechanical environment and shows potential for drug screening.
Executive Industry Relevance
Bridging the translational gap in aortic disease research requires physiologically relevant human models that recapitulate biomechanical strain. The HASMC organ-on-a-chip platform enables predictive interrogation of human aortic smooth muscle cell responses under controlled mechanical conditions, supporting target validation and mechanistic de-risking for thoracic aortic aneurysm and dissection (TAAD). This system enhances portfolio confidence by enabling disease-relevant, patient-derived modeling for early discovery and preclinical assessment.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses in a human biomechanical context.
- Supports mechanistic de-risking by modeling contractile phenotype and gene expression under strain.
- Facilitates functional target validation using patient-derived HASMCs from BAV-TAAD and TAV-TAAD cases.
- Improves predictive confidence for portfolio triage by recapitulating disease-relevant cellular responses.
Screening & Assay Development
- Prepares validated, strain-responsive HASMC systems for downstream compound evaluation.
- Standardizes biomechanical parameters for reproducible, quantitative readouts of cell alignment and marker expression.
- Enables screening of drug effects on contractile phenotype and viability in a controlled microenvironment.
- Supports scalability and platform reuse for multiple disease models and patient backgrounds.
Translational & Preclinical Research
- Aligns in vitro findings with native human aortic wall biology for translational continuity.
- Enables risk-adjusted advancement decisions by modeling patient-specific disease phenotypes.
- Provides a complementary alternative to animal models for preclinical mechanistic studies.
- Facilitates exploration of disease pathogenesis and therapeutic target discovery in TAAD.
Pipeline & Workflow Integration
This organ-on-a-chip model integrates into the discovery-to-preclinical continuum by enabling hypothesis testing, target validation, and early compound screening in a human-relevant biomechanical system.
- Discovery Biology: Supports pathway clarification and biological de-risking by modeling strain-induced gene and protein expression changes.
- Screening: Delivers reproducible, quantitative outputs for cell viability, alignment, and contractile marker expression under defined strain conditions.
- Analytics: Provides measurable endpoints for comparing static versus strain conditions and evaluating patient-derived cell responses.
- Translational Research: Connects in vitro mechanistic findings to disease-relevant phenotypes observed in human aortic tissue.
- Enterprise Reuse: Offers a modular, reusable platform adaptable to various aortic disease models and patient cohorts.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in aortic disease modeling.
- Operational Value: Standardizes biomechanical simulation and supports reproducibility across experiments.
- Strategic Value: Enables better go/no-go decisions and capital efficiency by providing human-relevant data early in the pipeline.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of TAAD therapeutic programs.
Implementation Considerations
- Requires expertise in microfluidics, cell culture, and biomechanical simulation.
- Demands access to precision fabrication, vacuum control, and analytical imaging infrastructure.
- Necessitates rigorous sterility and cross-team standardization for reproducible results.
- Adaptable to co-culture systems and additional mechanical forces, such as shear stress, as supported by protocol.
- Practical limitations include the need for patient-derived primary cells and careful handling of PDMS components.
Biopharma FAQs
Why does null hypothesis testing matter for HASMC strain response?
Null hypothesis testing enables objective evaluation of whether biomechanical strain induces significant changes in HASMC morphology, alignment, and contractile marker expression, supporting robust target validation in TAAD research.
How does independent variable isolation fit the organ-on-a-chip workflow?
The platform allows precise control of strain amplitude and frequency as independent variables, enabling systematic assessment of their effects on HASMC phenotype and gene expression for mechanistic de-risking.
What do quantitative dependent variable measurements enable in this model?
Quantitative readouts of cell viability, alignment, and contractile marker levels provide actionable data for comparing static and strain conditions, informing early screening and target confidence decisions.
Why are replication requirements critical for cross-functional HASMC-OOC studies?
Replication ensures reproducibility of biomechanical and phenotypic outputs across patient-derived samples, supporting cross-team data reliability and collaborative advancement of TAAD models.
What statistical analysis capabilities are required before implementing strain-based assays?
Robust statistical tools are needed to analyze differences in gene expression, protein markers, and cell morphology between experimental conditions, ensuring data-driven decision-making in R&D workflows.
Chapters in this video
0:04
Introduction
1:03
Primary Human Aortic Smooth Muscle Cell Isolation
2:53
Preparation of PDMS Chip
5:29
PDMS Chip Surface Treatment and Sterilization
6:12
Cell Seeding on the PDMS Chip and Cell Stretching Process
8:23
Preparation of the Mechanical Control System
9:30
Results: An HASMC‐Organ‐On‐A‐Chip Model to Precisely Control the Parameters of the Biomechanical Strain on the Aortic Wall
11:03
Conclusion
